Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

80.32 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna Inc

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
Via ACCESSWIRE
Upwork underscores the strength of the AI gig economy
Upwork has been pursuing its goal of being the world's preeminent destination for artificial intelligence (AI) related talent and freelancers 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
Via ACCESSWIRE
Moderna to Present at Upcoming Conferences in November 2023
Via ACCESSWIRE
Moderna Highlights its Digital and AI Strategy and Progress at Second Digital Investor Event
Via ACCESSWIRE
Moderna Tops BioSpace’s Best Places to Work Ranking for Third Consecutive Year
Via ACCESSWIRE
Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates
Via ACCESSWIRE
CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission
Via ACCESSWIRE
Moderna Named a Top Employer by Science for Ninth Consecutive Year
Via ACCESSWIRE
Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19
Via ACCESSWIRE
Moderna to Host Second Digital Investor Event on November 8th, 2023
Via ACCESSWIRE
Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023
Via ACCESSWIRE
Moderna Inc. (NASDAQ: MRNA) Making Surprising Moves in Wednesday Session
Via Investor Brand Network
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine
Via ACCESSWIRE
Moderna to Host Investor Event - R&D Day and Business Updates
Via ACCESSWIRE
Moderna Inc. (NASDAQ: MRNA) Highlighted for Surprising Price Action
Via Investor Brand Network
3 Undervalued Healthcare Stocks to Watch as Sector Struggles
As the healthcare sector slumps, several major stocks, including Zimmer Biomet, Moderna, and Illumina, appear undervalued in contrast to their intrinsic worth. 
Via MarketBeat
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
Via ACCESSWIRE
Moderna Recommends Shareholders Reject Amended “Mini-Tender” Offer by TRC Capital Investment Corporation
Via ACCESSWIRE
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s Updated Covid-19 Vaccine in The European Union
Via ACCESSWIRE
Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease
Via ACCESSWIRE
Moderna Inc. (NASDAQ: MRNA) is a Leading Gainer in 8/17 Morning Trading
Via Investor Brand Network
Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates
Via ACCESSWIRE
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Via ACCESSWIRE
Moderna Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
Via ACCESSWIRE
Moderna to Participate at Morgan Stanley 21st Annual Global Healthcare Conference
Via ACCESSWIRE
Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86
Via ACCESSWIRE
Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants
Via ACCESSWIRE
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.